Press releases
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
- Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
- Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
More ▼
Key statistics
On Friday, Atara Biotherapeutics Inc (AT2:BER) closed at 0.6266, 229.62% above the 52 week low of 0.1901 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6088 |
---|---|
High | 0.6266 |
Low | 0.6088 |
Bid | 0.5898 |
Offer | 0.6536 |
Previous close | 0.6136 |
Average volume | 2.00k |
---|---|
Shares outstanding | 120.42m |
Free float | 117.08m |
P/E (TTM) | -- |
Market cap | 80.68m USD |
EPS (TTM) | -2.61 USD |
Data delayed at least 15 minutes, as of May 03 2024 19:30 BST.
More ▼